benzylpenicilloyl polylysine

FDA Drug Profile — PRE-PEN

Drug Details

Generic Name
benzylpenicilloyl polylysine
Brand Names
PRE-PEN
Application Number
BLA050114
Sponsor
ALK-ABELLO, INC.
NDC Codes
1
Dosage Forms
INJECTION
Routes
INTRADERMAL, SUBCUTANEOUS
Active Ingredients
BENZYLPENICILLOYL POLYLYSINE

Indications and Usage

INDICATIONS AND USAGE: PRE-PEN is indicated for the assessment of sensitization to penicillin (benzylpenicillin or penicillin G) in patients suspected to have clinical penicillin hypersensitivity. A negative skin test to PRE-PEN is associated with an incidence of immediate allergic reactions of less than 5% after the administration of therapeutic penicillin, whereas the incidence may be more than 50% in a history-positive patient with a positive skin test to PRE-PEN. These allergic reactions are predominantly dermatologic. Whether a negative skin test to PRE-PEN predicts a lower risk of anaphylaxis is not established. Similarly, when deciding the risk of proposed penicillin treatment, there are not enough data at present to permit relative weighing in individual cases of a history of clinical penicillin hypersensitivity as compared to positive skin tests to PRE-PEN and/or minor penicillin determinants.

Warnings

WARNINGS: The risk of sensitization to repeated skin testing with PRE-PEN is not established. Rarely, a systemic allergic reaction including anaphylaxis (see below) may follow a skin test with PRE-PEN. To decrease the risk of a systemic allergic reaction, puncture skin testing should be performed first. Intradermal skin testing should be performed only if the puncture test is entirely negative.